ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway

Science Signaling

Volumn 3, Issue 108, 2010, Pages

  Kuo, Hsu Ping ^a,b   Lee, Dung Fang ^a,b   Chen, Chun Te ^a,b   Liu, Mo ^a,b   Chou, Chao Kai ^a,b   Lee, Hong Jen ^a,b   Du, Yi ^a,b   Xie, Xiaoming ^a,c   Wei, Yongkun ^a   Xia, Weiya ^a   Weihua, Zhang ^d   Yang, Jer Yen ^a,b   Yen, Chia Jui ^a   Huang, Tzu Hsuan ^a   Tan, Minjia ^e   Xing, Gang ^f   Zhao, Yingming ^e,f   Lin, Chien Hsing ^g   Tsai, Shih Feng ^g   Fidler, Isaiah J ^b,d   Hung, Mien Chie ^a,b,h,i   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARREST DEFECTIVE PROTEIN 1; CELL PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; TUBERIN; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ARD1A PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ACETYLATION; ARTICLE; AUTOPHAGY; BETA CHAIN; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEK293; CHROMOSOME XQ; CLONOGENESIS; CONTROLLED STUDY; ENHANCER REGION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SUMOYLATION; ALLELE; ANIMAL; BREAST TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; METABOLISM; MOUSE; TUMOR CELL LINE;

MAMMALIA;

ACETYLTRANSFERASES; ALLELES; ANIMALS; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROZYGOTE; HUMANS; MICE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 77951643083     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2000590     Document Type: Article

References (66)

1. J. M. Peralba, L. DeGraffenried, W. Friedrichs, L. Fulcher, V. Grünwald, G. Weiss, M. Hidalgo, Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, ARin cancer patients. Clin. Cancer Res. 9, 2887-2892 (2003).
2. A. Boulay, S. Zumstein-Mecker, C. Stephan, I. Beuvink, F. Zilbermann, R. Haller, S. Tobler, C. Heusser, T. O'Reilly, B. Stolz, A. Marti, G. Thomas H. A. Lane, Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64, 252-261 (2004).
3. A. D. Basso, A. Mirza, G. Liu, B. J. Long, W. R. Bishop, P. Kirschmeier, The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 280, 31101-31108 (2005).
4. E. J. Brown, P. A. Beal, C. T. Keith, J. Chen, T. B. Shin, S. L. Schreiber, Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377, 441-446 (1995).
5. G. J. Brunn, C. C. Hudson, A. Sekulic, J. M. Williams, H. Hosoi, P. J. Houghton, J. C. Lawrence Jr., R. T. Abraham, Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99-101 (1997).
6. K. Inoki, Y. Li, T. Zhu, J. Wu, K. L. Guan, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657 (2002).
7. K. Hara, K. Yonezawa, Q. P. Weng, M. T. Kozlowski, C. Belham, J. Avruch, Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273, 14484-14494 (1998).
8. P. B. Dennis, A. Jaeschke, M. Saitoh, B. Fowler, S. C. Kozma, G. Thomas, Mammalian TOR: A homeostatic ATP sensor. Science 294, 1102-1105 (2001).
9. K. Inoki, T. Zhu, K. L. Guan, TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003).
10. K. M. Hannan, Y. Brandenburger, A. Jenkins, K. Sharkey, A. Cavanaugh, L. Rothblum, T. Moss, G. Poortinga, G. A. McArthur, R. B. Pearson, R. D. Hannan, mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 23, 8862-8877 (2003).
11. N. Terada, H. R. Patel, K. Takase, K. Kohno, A. C. Nairn, E. W. Gelfand, Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. U. S. A. 91, 11477-11481 (1994).
12. A. C. Gingras, B. Raught, N. Sonenberg, Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15, 807-826 (2001).
13. R. C. Scott, O. Schuldiner, T. P. Neufeld, Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell 7, 167-178 (2004).
14. X. H. Liang, S. Jackson, M. Seaman, K. Brown, B. Kempkes, H. Hibshoosh, B. Levine, Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672-676 (1999).
15. S. Arico, A. Petiot, C. Bauvy, P. F. Dubbelhuis, A. J. Meijer, P. Codogno, E. Ogier-Denis, The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 276, 35243-35246 (2001).
16. W. Bursch, A. Ellinger, H. Kienzl, L. Török, S. Pandey, M. Sikorska, R. Walker, R. S. Hermann, Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: The role of autophagy. Carcinogenesis 17, 1595-1607 (1996).
17. Y. Shao, Z. Gao, P. A. Marks, X. Jiang, Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 101, 18030-18035 (2004).
18. A. R. Tee, D. C. Fingar, B. D. Manning, D. J. Kwiatkowski, L. C. Cantley, J. Blenis, Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U. S. A. 99, 13571-13576 (2002).
19. C. J. Potter, L. G. Pedraza, T. Xu, Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4, 658-665 (2002).
20. H. B. Jefferies, S. Fumagalli P. B. Dennis, C. Reinhard, R. B. Pearson, G. Thomas, Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 16, 3693-3704 (1997).
21. J. Montagne, M. J. Stewart, H. Stocker, E. Hafen, S. C. Kozma, G. Thomas, Drosophila S6 kinase: A regulator of cell size. Science 285, 2126-2129 (1999).
22. T. Radimerski, J. Montagne, F. Rintelen, H. Stocker, J. van der Kaay, C. P. Downes, E. Hafen, G. Thomas, dS6K-regulated cell growth is dPKB/dPI (3) K-independent, but requires dPDK1. Nat. Cell Biol. 4, 251-255 (2002).
23. N. Hay, N. Sonenberg, Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945 (2004).
24. D. C. Fingar, C. J. Richardson, A. R. Tee, L. Cheatham, C. Tsou, J. Blenis, mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24, 200-216 (2004).
25. D. C. Fingar, S. Salama, C. Tsou, E. Harlow, J. Blenis, Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16, 1472-1487 (2002).
26. H. Y. Cohen, S. Lavu, K. J. Bitterman, B. Hekking, T. A. Imahiyerobo, C. Miller, R. Frye, H. Ploegh, B. M. Kessler, D. A. Sinclair, Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627-638 (2004).
27. U. Mahlknecht, D. Hoelzer, Histone acetylation modifiers in the pathogenesis of malignant disease Mol. Med. 6, 623-644 (2000).
28. T. Arnesen, D. Anderson, C. Baldersheim, M. Lanotte, J. E. Varhaug, J. R. Lillehaug, Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem. J. 386, 433-443 (2005).
29. J. W. Jeong, M. K. Bae, M. Y. Ahn, S. H. Kim, T. K. Sohn, M. H. Bae, M. A. Yoo, E. J. Song, K. J. Lee, K. W. Kim, Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111, 709-720 (2002).
30. T. Arnesen, X. Kong, R. Evjenth, D. Gromyko, J. E. Varhaug, Z. Lin, N. Sang, J. Caro, J. R. Lillehaug, Interaction between HIF-1α (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1α FEBS Lett. 579, 6428-6432 (2005).
31. T. A. Murray-Rust, N. J. Oldham, K. S. Hewitson, C. J. Schofield, Purified recombinant hARD1 does not catalyse acetylation of Lys532 of HIF-α fragments in vitro. FEBS Lett. 580, 1911-1918 (2006).
32. M. Whiteway, J. W. Szostak, The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell 43, 483-492 (1985).
33. a acetylation is required for normal growth and mating of Saccharomyces cerevisiae. J. Bacteriol. 171, 5795-5802 (1989).
34. T. Arnesen, D. Gromyko, F. Pendino, A. Ryningen, J. E. Varhaug, J. R. Lillehaug, Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-α-acetyltransferase complex. Oncogene 25, 4350-4360 (2006).
35. C. H. Yi, D. K. Sogah, M. Boyce, A. Degterev, D. E. Christofferson, J. Yuan, A genome-wide RNAi screen reveals multiple regulators of caspase activation. J. Cell Biol. 179, 619-626 (2007).
36. J. H. Lim, J. W. Park, Y. S. Chun, Human arrest defective 1 acetylates and activates β-catenin, promoting lung cancer cell proliferation. Cancer Res. 66, 10677-10682 (2006).
37. A. Elfilali, S. Lair, C. Verbeke, P. La Rosa, F. Radvanyi, E. Barillot, ITTACA: A new database for integrated tumor transcriptome array and clinical data analysis. Nucleic Acids Res. 34, D613-D616 (2006).
38. E. Huang, S. H. Cheng, H. Dressman, J. Pittman, M. H. Tsou, C. F. Horng, A. Bild, E. S. Iversen, M. Liao, C. M. Chen, M. West, J. R. Nevins, A. T. Huang, Gene expression predictors of breast cancer outcomes. Lancetn 361, 1590-1596 (2003).
39. Y. M. Shiao, Y. H. Chang, Y. M. Liu, J. C. Li, J. S. Su, K. J. Liu, Y. F. Liu, M. W. Lin, S. F. Tsai, Dysregulation of GIMAP genes in non-small cell lung cancer. Lung Cancer 62, 287-294 (2008).
40. D. F. Lee, H. P. Kuo, M. Liu, C. K. Chou, W. Xia, Y. Du, J. Shen, C. T. Chen, L. Huo, M. C. Hsu, C. W. Li, Q. Ding, T. L. Liao, C. C. Lai, A. C. Lin, Y. H. Chang, S. F. Tsai, L. Y. Li, M. C. Hung, KEAP1 E3 ligase-mediated downregulation of NF-κB signaling by targeting IKKβ Mol. Cell 36, 131-140 (2009).
41. X. Xie, W. Xia, Z. Li, H. P. Kuo, Y. Liu, Z. Li, Q. Ding, S. Zhang, B. Spohn, Y. Yang, Y. Wei, J. Y. Lang, D. B. Evans, P. J. Chiao, J. L. Abbruzzese, M. C. Hung, Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12, 52-65 (2007).
42. M. Asaumi, K. Iijima, A. Sumioka, K. Iijima-Ando, Y. Kirino, T. Nakaya, T. Suzuki, Interaction of N-terminal acetyltransferase with the cytoplasmic domain of β-amyloid precursor protein and its effect on Aβ secretion. J. Biochem. 137, 147-155 (2005).
43. Abbreviations for the amino acids are as follows: A, Ala; D, Asp; E, Glu; F, Phe; G, Gly; I, Ile; K, Lys; L, Leu; M, Met; P, Pro; R, Arg; S, Ser; and T, Thr.
44. H. W. Lo, W. Xia, Y. Wei, M. Ali-Seyed, S. F. Huang, M. C. Hung, Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 65, 338-348 (2005).
45. T. S. Fisher, S. D. Etages, L. Hayes, K. Crimin, B. Li, Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J. Biol. Chem. 280, 17749-17757 (2005).
46. T. Noda, Y. Ohsumi, Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J. Biol. Chem. 273, 3963-3966 (1998).
47. D. D. Sarbassov, S. M. Ali, D. M. Sabatini, Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603 (2005).
48. T. Arnesen, D. Gromyko, O. Horvli, O. Fluge, J. Lillehaug, J. E. Varhaug, Expression of N-acetyl transferase human and human Arrest defective 1 proteins in thyroid neoplasms. Thyroid 15, 1131-1136 (2005).
49. T. Ren, B. Jiang, G. Jin, J. Li, B. Dong, J. Zhang, L. Meng, J. Wu, C. Shou, Generation of novel monoclonal antibodies and their application for detecting ARD1 expression in colorectal cancer. Cancer Lett. 264, 83-92 (2008).
50. M. L. Loupart, S. Adams, J. A. Armour, R. Walker, W. Brammar, J. Varley, Loss of heterozygosity on the X chromosome in human breast cancer. Genes Chromosomes Cancer 13, 229-238 (1995).
51. A. M. Kersemaekers, G. G. Kenter, J. Hermans, G. J. Fleuren, M. J. van de Vijver, Allelic loss and prognosis in carcinoma of the uterine cervix. Int. J. Cancer 79, 411-417 (1998).
52. L. Girard, S. Zöchbauer-Muller, A. K. Virmani, A. F. Gazdar, J. D. Minna, Genomewide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 60, 4894-4906 (2000).
53. C. Tribioli, M. Mancini, E. Plassart, S. Bione, S. Rivella, C. Sala, G. Torri, D. Toniolo, Isolation of new genes in distal Xq28: Transcriptional map and identification of a human homologue of the ARD1 N-acetyl transferase of Saccharomyces cerevisiae. Hum. Mol. Genet. 3, 1061-1067 (1994).
54. X. J. Shen, R. Ali-Fehmi, C. R. Weng, F. H. Sarkar, D. Grignon, D. J. Liao, Loss of heterozygosity and microsatellite instability at the Xq28 and the A/G heterozygosity of the QM gene are associated with ovarian cancer. Cancer Biol. Ther. 5, 523-528 (2006).
55. J. Edelmann, K. Richter, C. Hänel, S. Hering, L. C. Horn, X chromosomal and autosomal loss of heterozygosity and microsatellite instability in human cervical carcinoma. Int. J. Gynecol. Cancer 16, 1248-1253 (2006).
56. A. F. Chambers, MDA-MB-435 and M14 cell lines: Identical but not M14 melanoma? Cancer Res. 69, 5292-5293 (2009).
57. S. Sellappan, R. Grijalva, X. Zhou, W. Yang, M. B. Eli, G. B. Mills, D. Yu, Lineage infidelity of MDA-MB-435 cells: Expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 64, 3479-3485 (2004).
58. Y. Zou, H. Peng, B. Zhou, Y. Wen, S. C. Wang, E. M. Tsai, M. C. Hung, Systemic tumor suppression by the proapoptotic gene bik. Cancer Res. 62, 8-12 (2002).
59. C. Ma, J. Wang, J. Luo, Exposure to asphalt fumes activates activator protein-1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in mouse epidermal cells. J. Biol. Chem. 278, 44265-44272 (2003).
60. J. Y. Chang, W. Xia, R. Shao, F. Sorgi, G. N. Hortobagyi, L. Huang, M. C. Hung, The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14, 561-568 (1997).
61. S. Yaguchi, Y. Fukui, I. Koshimizu, H. Yoshimi, T. Matsuno, H. Gouda, S. Hirono, K. Yamazaki, T. Yamori, Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst. 98, 545-556 (2006).
62. L. Lee, P. Sudentas, B. Donohue, K. Asrican, A. Worku, V. Walker, Y. Sun, K. Schmidt, M. S. Albert, N. El-Hashemite, A. S. Lader, H. Onda, H. Zhang, D. J. Kwiatkowski, S. L. Dabora, Efficacy of a rapamycin analog (CCI-779) and IFN-ε in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42, 213-227 (2005).
63. M. C. Hu, D. F. Lee, W. Xia, L. S. Golfman, F. Ou-Yang, J. Y. Yang, Y. Zou, S. Bao, N. Hanada, H. Saso, R. Kobayashi, M. C. Hung, IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237 (2004).
64. D. F. Lee, H. P. Kuo, C. T. Chen, J. M. Hsu, C. K. Chou, Y. Wei, H. L. Sun, L. Y. Li, B. Ping, W. C. Huang, X. He, J. Y. Hung, C. C. Lai, Q. Ding, J. L. Su, J. Y. Yang, A. A. Sahin, G. N. Hortobagyi, F. J. Tsai, C. H. Tsai, M. C. Hung, IKK βsuppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455 (2007).
65. A. Singh, V. Misra, R. K. Thimmulappa, H. Lee, S. Ames, M. O. Hoque, J. G. Herman, S. B. Baylin, D. Sidransky, E. Gabrielson, M. V. Brock, S. Biswal, Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3, e420 (2006).
66. Acknowledgments: We thank D. J. Kwiatkowski, J. Blenis, and K.-L. Guan for providing the cells and constructs; S. Zhang, J. Shi, B. Spohn, J.-F. Lee, Z. Han, H.-W. Yeh, T.-L. Liao, Y.-H. Chang, and K. Dunner Jr., for their technical support; The University of Texas M. D. Anderson Cancer Center (MDACC) Institutional Core Grant CA16672 High Resolution Electron Microscopy facility for electron microscopy analysis; The University of Texas MDACC DNA Core Facility for fluorescent DNA fragment analysis; and the Department of Scientific Publications at M. D. Anderson for editing this manuscript. This work was partially supported by NIH grants R01 CA109311, CCSG CA16672, and P01 CA099031; M. D. Anderson Specialized Programs of Research Excellence grants (P50 CA116199 for breast Cancer and P50 CA83639 for ovarian cancer), MDACC-China Medical University and Hospital Sister Institution Fund, Patel Memorial Breast Cancer Endowment Fund, and grants from the Kadoorie Charitable Foundations, the National Breast Cancer Foundation, Inc., and Taiwan National Science Council (NSC-96-3111-B) to M.-C. H.; a grant R01 CA126832 to Y. Z.; a predoctoral fellowship from the U. S. Army Breast Cancer Research Program (grant W81XWH-08-1-0397), and the Andrew Sowell-Wade Huggins Scholarship from the University of Texas Graduate School of Biomedical Sciences at Houston to H.-P. K.; a predoctoral fellowship from the U. S. Army Breast Cancer Research Program (grant W81XWH-05-1-0252) and the T. C. Hsu Endowed Memorial Scholarship, Andrew Sowell-Wade Huggins Scholarship and Presidents' Research Scholarship from the University of Texas Graduate School of Biomedical Sciences at Houston to D.-F. L.; a predoctoral fellowship from the U. S. Army Breast Cancer Research Program (grant W81XWH-06-1-0709) to C.-K. C.; and a research assistant scholarship from the University of Texas Graduate School of Biomedical Sciences at Houston to M. L.